(BAX) Baxter International - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0718131099
Stock:
Total Rating 33
Risk 80
Buy Signal -1.25
| Risk 5d forecast | |
|---|---|
| Volatility | 39.4% |
| Relative Tail Risk | -16.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.10 |
| Alpha | -58.19 |
| Character TTM | |
|---|---|
| Beta | 0.850 |
| Beta Downside | 1.153 |
| Drawdowns 3y | |
|---|---|
| Max DD | 62.44% |
| CAGR/Max DD | -0.31 |
EPS (Earnings per Share)
Revenue
Description: BAX Baxter International
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -957.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.56 > 1.0 |
| NWC/Revenue: 34.70% < 20% (prev 22.02%; Δ 12.68% < -1%) |
| CFO/TA 0.04 > 3% & CFO 845.0m > Net Income -957.0m |
| Net Debt (7.81b) to EBITDA (766.0m): 10.20 < 3 |
| Current Ratio: 2.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (514.0m) vs 12m ago 0.78% < -2% |
| Gross Margin: 30.05% > 18% (prev 0.36%; Δ 2969 % > 0.5%) |
| Asset Turnover: 49.06% > 50% (prev 41.25%; Δ 7.81% > 0%) |
| Interest Coverage Ratio: -0.74 > 6 (EBITDA TTM 766.0m / Interest Expense TTM 290.0m) |
Altman Z'' 4.24
| A: 0.19 (Total Current Assets 6.87b - Total Current Liabilities 2.97b) / Total Assets 20.05b |
| B: 0.68 (Retained Earnings 13.71b / Total Assets 20.05b) |
| C: -0.01 (EBIT TTM -215.0m / Avg Total Assets 22.92b) |
| D: 0.76 (Book Value of Equity 10.63b / Total Liabilities 13.95b) |
| Altman-Z'' Score: 4.24 = AA |
Beneish M -2.88
| DSRI: 1.06 (Receivables 1.93b/1.73b, Revenue 11.24b/10.64b) |
| GMI: 1.21 (GM 30.05% / 36.30%) |
| AQI: 0.93 (AQ_t 0.50 / AQ_t-1 0.53) |
| SGI: 1.06 (Revenue 11.24b / 10.64b) |
| TATA: -0.09 (NI -957.0m - CFO 845.0m) / TA 20.05b) |
| Beneish M-Score: -2.88 (Cap -4..+1) = A |
What is the price of BAX shares?
As of March 04, 2026, the stock is trading at USD 19.03 with a total of 7,855,826 shares traded.
Over the past week, the price has changed by -7.71%, over one month by -4.37%, over three months by +0.79% and over the past year by -44.66%.
Over the past week, the price has changed by -7.71%, over one month by -4.37%, over three months by +0.79% and over the past year by -44.66%.
Is BAX a buy, sell or hold?
Baxter International has received a consensus analysts rating of 3.44.
Therefor, it is recommend to hold BAX.
- StrongBuy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.6 | 13.7% |
| Analysts Target Price | 21.6 | 13.7% |
BAX Fundamental Data Overview March 01, 2026
P/E Forward = 8.8417
P/S = 0.9321
P/B = 1.7091
P/EG = 36.6767
Revenue TTM = 11.24b USD
EBIT TTM = -215.0m USD
EBITDA TTM = 766.0m USD
Long Term Debt = 9.47b USD (from longTermDebt, last quarter)
Short Term Debt = 82.0m USD (from shortTermDebt, last quarter)
Debt = 9.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.81b USD (from netDebt column, last quarter)
Enterprise Value = 18.29b USD (10.48b + Debt 9.78b - CCE 1.97b)
Interest Coverage Ratio = -0.74 (Ebit TTM -215.0m / Interest Expense TTM 290.0m)
EV/FCF = 56.64x (Enterprise Value 18.29b / FCF TTM 323.0m)
FCF Yield = 1.77% (FCF TTM 323.0m / Enterprise Value 18.29b)
FCF Margin = 2.87% (FCF TTM 323.0m / Revenue TTM 11.24b)
Net Margin = -8.51% (Net Income TTM -957.0m / Revenue TTM 11.24b)
Gross Margin = 30.05% ((Revenue TTM 11.24b - Cost of Revenue TTM 7.87b) / Revenue TTM)
Gross Margin QoQ = 19.40% (prev 33.51%)
Tobins Q-Ratio = 0.91 (Enterprise Value 18.29b / Total Assets 20.05b)
Interest Expense / Debt = 0.71% (Interest Expense 69.0m / Debt 9.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -169.8m (EBIT -215.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.31 (Total Current Assets 6.87b / Total Current Liabilities 2.97b)
Debt / Equity = 1.60 (Debt 9.78b / totalStockholderEquity, last quarter 6.13b)
Debt / EBITDA = 10.20 (Net Debt 7.81b / EBITDA 766.0m)
Debt / FCF = 24.19 (Net Debt 7.81b / FCF TTM 323.0m)
Total Stockholder Equity = 6.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.18% (Net Income -957.0m / Total Assets 20.05b)
RoE = -13.78% (Net Income TTM -957.0m / Total Stockholder Equity 6.94b)
RoCE = -1.31% (EBIT -215.0m / Capital Employed (Equity 6.94b + L.T.Debt 9.47b))
RoIC = -1.02% (negative operating profit) (NOPAT -169.8m / Invested Capital 16.58b)
WACC = 4.95% (E(10.48b)/V(20.26b) * Re(9.05%) + D(9.78b)/V(20.26b) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.49%
[DCF] Terminal Value 80.82% ; FCFF base≈417.4m ; Y1≈274.0m ; Y5≈125.0m
[DCF] Fair Price = N/A (negative equity: EV 3.98b - Net Debt 7.81b = -3.83b; debt exceeds intrinsic value)
EPS Correlation: -71.28 | EPS CAGR: -18.09% | SUE: -0.88 | # QB: 0
Revenue Correlation: -71.53 | Revenue CAGR: -5.71% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.44 | Chg7d=-0.119 | Chg30d=-0.119 | Revisions Net=-9 | Analysts=14
EPS current Year (2026-12-31): EPS=1.92 | Chg7d=+0.001 | Chg30d=-0.341 | Revisions Net=-14 | Growth EPS=-15.5% | Growth Revenue=+1.0%
EPS next Year (2027-12-31): EPS=2.06 | Chg7d=+0.003 | Chg30d=-0.396 | Revisions Net=-10 | Growth EPS=+7.4% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Next Quarter)
P/S = 0.9321
P/B = 1.7091
P/EG = 36.6767
Revenue TTM = 11.24b USD
EBIT TTM = -215.0m USD
EBITDA TTM = 766.0m USD
Long Term Debt = 9.47b USD (from longTermDebt, last quarter)
Short Term Debt = 82.0m USD (from shortTermDebt, last quarter)
Debt = 9.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.81b USD (from netDebt column, last quarter)
Enterprise Value = 18.29b USD (10.48b + Debt 9.78b - CCE 1.97b)
Interest Coverage Ratio = -0.74 (Ebit TTM -215.0m / Interest Expense TTM 290.0m)
EV/FCF = 56.64x (Enterprise Value 18.29b / FCF TTM 323.0m)
FCF Yield = 1.77% (FCF TTM 323.0m / Enterprise Value 18.29b)
FCF Margin = 2.87% (FCF TTM 323.0m / Revenue TTM 11.24b)
Net Margin = -8.51% (Net Income TTM -957.0m / Revenue TTM 11.24b)
Gross Margin = 30.05% ((Revenue TTM 11.24b - Cost of Revenue TTM 7.87b) / Revenue TTM)
Gross Margin QoQ = 19.40% (prev 33.51%)
Tobins Q-Ratio = 0.91 (Enterprise Value 18.29b / Total Assets 20.05b)
Interest Expense / Debt = 0.71% (Interest Expense 69.0m / Debt 9.78b)
Taxrate = 21.0% (US default 21%)
NOPAT = -169.8m (EBIT -215.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.31 (Total Current Assets 6.87b / Total Current Liabilities 2.97b)
Debt / Equity = 1.60 (Debt 9.78b / totalStockholderEquity, last quarter 6.13b)
Debt / EBITDA = 10.20 (Net Debt 7.81b / EBITDA 766.0m)
Debt / FCF = 24.19 (Net Debt 7.81b / FCF TTM 323.0m)
Total Stockholder Equity = 6.94b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.18% (Net Income -957.0m / Total Assets 20.05b)
RoE = -13.78% (Net Income TTM -957.0m / Total Stockholder Equity 6.94b)
RoCE = -1.31% (EBIT -215.0m / Capital Employed (Equity 6.94b + L.T.Debt 9.47b))
RoIC = -1.02% (negative operating profit) (NOPAT -169.8m / Invested Capital 16.58b)
WACC = 4.95% (E(10.48b)/V(20.26b) * Re(9.05%) + D(9.78b)/V(20.26b) * Rd(0.71%) * (1-Tc(0.21)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.49%
[DCF] Terminal Value 80.82% ; FCFF base≈417.4m ; Y1≈274.0m ; Y5≈125.0m
[DCF] Fair Price = N/A (negative equity: EV 3.98b - Net Debt 7.81b = -3.83b; debt exceeds intrinsic value)
EPS Correlation: -71.28 | EPS CAGR: -18.09% | SUE: -0.88 | # QB: 0
Revenue Correlation: -71.53 | Revenue CAGR: -5.71% | SUE: 0.10 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.44 | Chg7d=-0.119 | Chg30d=-0.119 | Revisions Net=-9 | Analysts=14
EPS current Year (2026-12-31): EPS=1.92 | Chg7d=+0.001 | Chg30d=-0.341 | Revisions Net=-14 | Growth EPS=-15.5% | Growth Revenue=+1.0%
EPS next Year (2027-12-31): EPS=2.06 | Chg7d=+0.003 | Chg30d=-0.396 | Revisions Net=-10 | Growth EPS=+7.4% | Growth Revenue=+2.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 9 Down within 30d for Next Quarter)